CDI 45205
Alternative Names: CDI-45205Latest Information Update: 28 Apr 2025
At a glance
- Originator Kansas state university research foundation
- Developer Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronavirus infections; COVID 2019 infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Inhalation)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Intraperitoneal, Injection)
- 28 Jan 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Inhalation)